Design of the PID Evaluation and Clinical Health (PEACH) Study

Controlled Clinical Trials

Volumn 19, Issue 5, 1998, Pages 499-514

  Ness, Roberta B ^a   Soper, David E ^b   Peipert, Jeff ^c   Sondheimer, Steven J ^d   Holley, Robert L ^e   Sweet, Richard L ^f   Hemsell, David L ^g   Randall, Hugh ^h   Hendrix, Susan L ⁱ   Bass, Debra C ^a   Kelsey, Sheryl F ^a   Songer, Thomas J ^a   Lave, Judith R ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c WOMEN AND INFANTS HOSPITAL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h EMORY UNIVERSITY   (United States)

ⁱ WAYNE STATE UNIVERSITY   (United States)

Author keywords

Adnexitis; Clinical trials; Infertility; Pelvic inflammatory disease

Indexed keywords

ANTIBIOTIC AGENT; CEFOXITIN; DOXYCYCLINE; PROBENECID;

ADNEXITIS; ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG EFFICACY; FEMALE; FOLLOW UP; HOSPITAL PATIENT; HUMAN; INFERTILITY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OUTPATIENT; PATIENT SELECTION; PELVIC INFLAMMATORY DISEASE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032189964     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(98)00022-1     Document Type: Article

References (86)

1. Aral S.O., Mosher W.D., Cates W. Self-reported pelvic inflammatory disease in the US. a common occurrence JAMA. 266:1991;2570-2573.
2. Westrom L., Joesoef R., Reynolds G.et al. Pelvic inflammatory disease and fertility. a cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic findings Sex Transm Dis. 19:1992;185-192.
3. Westrom L., Mardh P.-A. Acute pelvic inflammatory disease (PID). Holmes K.K., Mardh P.-A., Sparling P.F. Sexually Transmitted Diseases. 2:1990;McGraw-Hill Company, New York.
4. Sweet R.L. Pelvic inflammatory disease and infertility in women. Infect Dis Clin N Am. 1:1987;199-215.
5. Blount J.H., Reynolds G.H., Rice R.J. Pelvic inflammatory disease. incidence and trends in private practice MMWR. 32:1983;27SS-34SS.
6. Rolfs R.T., Galaid E.I., Zaidi A.A. Pelvic inflammatory disease. trends in hospitalizations and office visits in the U.S., 1979-88 Am J Obstet Gynecol. 166:1992;983-990.
7. Washington A.E., Katz P. Cost of and payment source for pelvic inflammatory disease. trends and projections, 1983 through 2000 JAMA. 266:1991;2565-2569.
8. Brunham R.C., Binns B., Guijon F.et al. Etiology and outcome of acute pelvic inflammatory disease. J Infect Dis. 158:1988;510-517.
9. Peterson H.B., Walker C.K., Kahn J.G.et al. Pelvic inflammatory disease. key treatment issues and options JAMA. 266:1991;2605-2611.
10. MMWR, 1993 Sexually Transmitted Diseases Treatment Guidelines. U.S. DHHSPHS, September 24;42(RR-14):75-81.
11. Freeman W.L., Green L.A., Becker L.A. Pelvic inflammatory disease in primary care. Fam Med. 20:1988;192-196.
12. Cates W. Jr., Rolfs R.T. Jr., Aral S.O. Sexually transmitted diseases, pelvic inflammatory disease, and infertility. an epidemiologic update Epidemiol Rev. 12:1990;199-220.
13. Ness R.B., Delaney K., Rolfs R.T.et al. Practice variability in the inpatient treatment of pelvic inflammatory disease. J Wom Health. 4:1995;531-539.
14. Gunning J. A comparison of parenteral sulbactam/ampicillin versus clindamycin/gentamicin in the treatment of pelvic inflammatory disease. Drugs. 31:1986;14-17.
15. Larsen J.W. Jr., Voise C.T., Grossman J.H. Jr. Comparison of cefoxitin and clindamycin-gentamicin for pelvic infections. Clin Ther. 9:1986;77-83.
16. Gall S.A., Constantine L. Comparative evaluation of clindamycin versus clindamycin plus tobramycin in the treatment of acute pelvic inflammatory disease. Obstet Gynecol. 75:1990;282-286.
17. Walters M.D., Gibbs R.S. A randomized comparison of gentamicin-clindamycin and cefoxitin-doxycycline in the treatment of acute pelvic inflammatory disease. Obstet Gynecol. 75:1990;867-872.
18. Apuzzio J.J., Stankiewicz R., Jain S.et al. Comparison of parenteral ciprofloxacin with clindamycin-gentamicin in the treatment of pelvic infection. Am J Med. 87:1989;148S.
19. Sweet RL, Schachter J, Ohm-Smith M. Treatment of acute PID: cefoxitin plus doxycycline versus clindamycin plus tobramycin. Presented at the 1985 Interscience Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, MN, September 29-October 2, 1985 [Abstract 271].
20. Landers D.V., Wolner-Hanssen P., Paavonen J.et al. Combination antimicrobial therapy in the treatment of acute pelvic inflammatory disease. Am J Obstet Gynecol. 164:1991;849-858.
21. Obwegeser J., Kunz J., Wust J.et al. Clinical efficacy of amoxycillin/clavulanate in laparoscopically confirmed salpingitis. J Antimicrob Chemother. 24:1989;165-176.
22. Crombleholme W.R., Landers D., Ohm-Smith M.et al. Sulbactam/ampicillin versus metronidazole/gentamicin in the treatment of severe pelvic infections. Drugs. 31:1986;11-13.
23. Hemsell D.L., Hemsell P.G., Heard M.C.et al. Piperacillin and a combination of clindamycin and gentamicin for the treatment of hospital and community acquired acute pelvic infections including pelvic abscess. Surg Gynecol Obstet. 165:1987;223-229.
24. Dodson M.G., Faro S., Gentry L.O. Treatment of acute pelvic inflammatory disease with aztreonam, a new monocyclic-lactam antibiotic, and clindamycin. Obstet Gynecol. 67:1986;657-662.
25. Pastorek J.G. II, Cole C., Aldridge K.E.et al. Aztreonam plus clindamycin as therapy for pelvic infections in women. Am J Med. 78:1985;47-50.
26. Bruhat M.A., LeBouedec G., Pouly J.L.et al. Treatment of acute salpingitis with sulbactam/ampicillin. Int J Gynaecol Obstet. 2:1989;41-46.
27. Hemsell D.L., Wendel G.D., Gall S.A.et al. Multi-center comparison of cefotetan and cefoxitin in the treatment of acute obstetric and gynecologic infections. Am J Obstet Gynecol. 158:1988;722-727.
28. Hemsell D.L., Heard M.C., Hemsell P.G.et al. Sulbactam/ampicillin versus lefoxitin for uncomplicated and complicated acute pelvic inflammatory disease. Drugs. 34:1988;39-42.
29. Hemsell D.L., Nobles B.J., Heard M.C.et al. Upper and lower reproductive tract bacteria in 126 women with acute pelvic inflammatory disease. microbial susceptibility and clinical response to four therapeutic regimens J Reprod Med. 33:1988;799-805.
30. Poindexter A.N., Ritter M., Faro S.et al. Results of noncomparative studies of cefotetan in the treatment of obstetric and gynecologic infections. Am J Obstet Gynecol. 158:1988;717-721.
31. Faro S., Martens M.G., Phillips L.E.et al. Ceftizoxime versus cefotaxime in the treatment of hospitalized patients with pelvic inflammatory disease. Curr Ther Res. 43:1988;349-354.
32. Heinonen P.K., Teisala K., Punnonen R.et al. Treating pelvic inflammatory disease with doxycycline and metronidazole or penicillin and metronidazole. Genitourin Med. 62:1986;235-239.
33. Brihmer C., Brundin J. Second-look laparoscopy after treatment of acute salpingitis with doxycycline/benzylpenicillin procaine or trimethoprim-sulfamethoxazole. Scand J Infect Dis. 53:1988;65-69.
34. McGregor J.A., Christiansen F.B. Treatment of obstetric and gynecologic infections, with an emphasis on beta-lactamase-producing organism. J Reprod Med. 33:1988;591-594.
35. Heinonen P.K., Teisala K., Aine R.et al. Intravenous and oral ciprofloxacin in the treatment of proven pelvic inflammatory disease. a comparison of ciprofloxacin with doxycycline plus metronidazole Am J Med. 87:1989;152S-156S.
36. Sweet R.L., Schachter J., Landers D.V.et al. Treatment of hospitalized patients with acute pelvic inflammatory disease. comparison of cefotetan plus doxycycline and cefoxitin plus doxycycline Am J Obstet Gynecol. 158:1988;736-741.
37. Soper D.E., Despres B. A comparison of two antibiotic regimens for treatment of pelvic inflammatory disease. Obstet Gynecol. 72:1988;7-12.
38. Wasserheit J.N., Bell T.A., Kiviat N.B.et al. Microbial causes of proven pelvic inflammatory disease and efficacy of clindamycin and tobramycin. Ann Intern Med. 104:1986;187-193.
39. Crombleholme W.R., Schachter J., Ohm-Smith M.et al. Efficacy of single-agent therapy for the treatment of acute pelvic inflammatory disease with ciprofloxacin. Am J Med. 87:1989;142S-147S.
40. Sweet R.L., Landers D.V., Schachter J.et al. Sulbactam/ampicillin in the treatment of acute pelvic inflammatory disease. Int J Gynaecol Obstet. 2:1989;13-19.
41. Sweet R.L. Comparison of cefotetan plus doxycycline with cefoxitin plus doxycycline in the inpatient treatment of acute salpingitis. Sex Transm Dis. 18:1991;119-123.
42. Teisala K., Heinonen P.K., Aine R. Second laparoscopy after treatment of acute pelvic inflammatory disease. Obstet Gynecol. 69:1987;343-346.
43. American Hospital Formulary Service. Antibiotics American Society of Hospital Pharmacists; 1990.
44. Wolner-Hanssen P., Paavonen J., Kiviat N.et al. Outpatient treatment of pelvic inflammatory disease with cefoxitin and doxycycline. Obstet Gynecol. 71:1988;595-600.
45. Kosseim M., Ronald A., Plummer F.A.et al. Treatment of acute pelvic inflammatory disease in the ambulatory setting. trial of cefoxitin and doxycycline versus ampicillin-sulbactam Antimicrob Agents Chemother. 35:1991;1651-1656.
46. Katz B.P., Zwicki B.W., Caine V.A.et al. Compliance with antibiotic therapy for Chlamydia trachomatis and Neisseria gonorrhoeae. Sex Transm Dis. 19:1992;351-354.
47. Mardh P.-A. Pelvic inflammatory disease and related disorders; novel observations. Scand J Infect Dis. S69:1990;83-87.
48. Hasselquist M.B., Hillier S. Susceptibility of upper gential tract isolates from women with pelvic inflammatory disease to ampicillin, cefpodoxime, metronidazole, and doxycycline. Sex Transm Dis. 18:1991;146-149.
49. Kahn J.G., Walker C.K., Washington E.et al. Diagnosing pelvic inflammatory disease. a comprehensive analysis and considerations for developing a new model JAMA. 266:1991;2594-2604.
50. Sweet R.L., Draper D.L., Schachter J.et al. Microbiology and pathogenesis of acute salpingitis as determined by laparoscopy. what is the appropriate site to sample? Am J Obstet Gynecol. 138:1980;985-989.
51. Kiviat N.B., Wolner-Hanssen P., Eschenbach D.A.et al. Endometrial histology in patients with culture-proved upper genital tract infection laparoscopically diagnosed acute salpingitis. Am J Surg Pathol. 14:1990;167-175.
52. Jacobson L., Laurell C.-B., Gennser G.et al. Plasma protein changes induced by acute inflammation of the fallopian tubes. Int J Gynaecol Obstet. 13:1975;249.
53. Wolner-Hanssen P., Svensson L., Mardh P.-A.et al. Laparoscopic findings and contraceptive use in women with signs and symptoms suggestive of acute salpingitis. Obstet Gynecol. 66:1985;233-238.
54. Paavonen J., Kiviat N., Brunham R.C.et al. Prevalence and manifestations of endometritis among women with cervicitis. Am J Obstet Gynecol. 152:1985;280-286.
55. Lehtinen M., Laine S., Heinonen P.K.et al. Serum C-reactive protein determination in acute pelvic inflammatory disease. Am J Obstet Gynecol. 154:1986;158-159.
56. Aaran RK, Lehtinen M, Kallioniemi OP et al. Serum Ca 125 and TAT1 levels in inpatients and outpatients with pelvic inflammatory disease. Copenhagen, Denmark: Eighth Meeting of the International Society for Sexually Transmitted Disease Research; September 11, 1989 [abstract].
57. Semchyshyn S., Strickler R.C. Laparoscopy. is it replacing clinical acumen? Obstet Gynecol. 48:1976;615-618.
58. Chaparro M.V., Ghosh S., Nashed A.et al. Laparoscopy for the confirmation and prognostic evaluation of pelvic inflammatory disease. Int J Gynaecol Obstet. 15:1978;307-309.
59. Allen L.A., Schoon M.G. Laparoscopic diagnosis of acute pelvic inflammatory disease. Br J Obstet Gynaecol. 90:1983;966-968.
60. Henry-Suchet J. Laparoscopic diagnosis and treatment of PID. Keith L.G., Berger G.S., Edelman D.A. Infections in Reproductive Health Vol. 1. Common Infections. 1984;MTP Press Ltd, Lancaster, England.
61. Brihmer C., Kallings I., Nord C.-E.et al. Salpingitis, aspects of diagnosis and etiology. a 4-year study from a Swedish hospital Eur J Obstet Gynecol Reprod Biol. 24:1987;211-220.
62. Sellors J., Mahony J., Goldsmith C.et al. The accuracy of clinical findings and laparoscopy in pelvic inflammatory disease. Am J Obstet Gynecol. 164:1991;113-120.
63. Meinert C. Clinical Trials, Design, Conduct and Analysis. 1986;Oxford University Press, New York.
64. Washington A.E., Aral S.O., Wolner-Hanssen P.et al. Assessing risk for pelvic inflammatory disease and its sequalae. JAMA. 266:1991;2581-2586.
65. Eschenbach D.A. Epidemiology and diagnosis of acute pelvic inflammatory disease. Obstet Gynecol. 55:1980;142S-153S.
66. Ness R.B., Keder L.M., Soper D.E.et al. Oral contraception and the recognition of endometritis. Am J Obstet Gynecol. 176:1997;580-585.
67. Jacobson L., Westrom L. Objectivized diagnosis of acute pelvic inflammatory disease. Am J Obstet Gynecol. 105:1969;1088-1098.
68. Rudd P., Ahmed S., Zachary V.et al. Improved compliance measures. applications in an ambulatory hypertensive drug trial Clin Pharmacol Ther. 48:1990;676-685.
69. Norell S. Monitoring compliance with pilocarpine therapy. Am J Ophthalmol. 92:1981;727-731.
70. Ware J.E. Jr. SF-36 Health Survey Manual and Interpretation Guide. 1993;The Health Institute, New England Medical Center, Boston, MA.
71. Abbey A., Andrews F.M., Halman L.J. Gender's role in responses to infertility. Psychol Wom Quart. 15:1991;295-316.
72. Daut R.L., Cleeland C.S., Flanery R.C. Development of the Wisconsin Brief Pain questionnaire to assess pain in cancer and other disease. Pain. 17:1983;197-210.
73. McCormack W.M., Nowroozi K., Albert S.et al. Acute pelvic inflammatory disease. characteristics of patients with gonococcal and non-gonococcal infection and evaluation of their response to treatment with aqueous procaine penicillin G and spectinomycin hydrocholoride Sex Transm Dis. 4:1977;125-131.
74. Davies A.R., Ware J.E. GHAA's Consumer Satisfaction Survey. 1991;Group Health Association of America, Washington, D.C.
75. Winfield A.C., Wentz A.C. Diagnostic Imaging of Infertility. 1987;Williams and Wilkins, Baltimore, MD.
76. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 50:1966;163-170.
77. Cox D.B. Regression models and life tables. J Royal Stat Soc Ser B. 34:1972;187.
78. Slap G.B., Schwartz J.S. Risk factors for low birth weight to adolescent mothers. J Adoles Health Care. 10:1989;267-274.
79. Engelman L. Stepwise logistic regression. Dixon W.J., Brown M.B., Engelman L. BMDP Statistical Software. 1985;University of California Press, Berkeley, CA.
80. Hanley J.A., McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 143:1982;29-36.
81. Mercer L.J. Pelvic inflammatory disease. decision-making in the pharmacy and therapeutics committee J Reprod Med. 33:1988;135-141.
82. Arredondo J.L., Diaz V., Gaitan H.et al. Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients. Clin Infect Dis. 24:1997;170-178.
83. Safrin S., Schachter J., Dahrouge D.et al. Long-term sequelae of acute pelvic inflammatory disease. a retrospective cohort study Am J Obstet Gynecol. 166:1992;1300-1305.
84. Soper D., Ness R.B. Pelvic inflammatory disease and involuntary infertility. prospective pilot observations Infect Dis Obstet Gynecol. 3:1995;145-148.
85. Barad D.H. Epidemiology of infertility. Infert Reprod Med Clin N Am. 2:1991;255.
86. Fleiss J.L. Statistical methods for rates and proportions. 2:1981;Wiley & Sons, New York.